|
33 sessions found from the search. Tuesday May 3, 2011
Tue, 3 May 10:00 - 10:15 | OPENING TALK  SPEECH
| Room GABRIEL DELORME |
Speaker: J.P. FERMAND (FRANCE), T. FACON (FRANCE), P. MOREAU (FRANCE) |
Tue, 3 May 10:15 - 12:15 | MOLECULAR PATHWAYS / GENETICS PLENARY SESSION I | Room GABRIEL DELORME |
Chair: H. AVET-LOISEAU (FRANCE), M. CHESI (UNITED STATES) 10:15 - 10:25 Introduction H. AVET-LOISEAU (FRANCE) 10:25 - 11:05 Introduction lecture: physiopathology of Myeloma. What role for MicroRNAs? C.M. CROCE (UNITED STATES) 11:05 - 11:25 The different subtypes of Myeloma R. FONSECA (UNITED STATES) 11:25 - 11:55 The genetic progression of Myeloma S. MINVIELLE (FRANCE) |
Tue, 3 May 12:15 - 14:00 | LUNCH BREAK | |
12:15 - 14:00 Visit of exhibition & poster area |
Tue, 3 May 14:00 - 15:45 | PLASMA CELL BIOLOGY PLENARY SESSION I | Room GABRIEL DELORME |
Chair: B. KLEIN (FRANCE), N. MUNSHI (UNITED STATES) 14:00 - 14:25 Introduction lecture: "the UPR system" A.H. LEE (UNITED STATES) 14:25 - 14:45 Cytokine pathways: which one to target? B. KLEIN (FRANCE) 14:45 - 15:05 mTOR complex pathway in Myeloma A. LICHTENSTEIN (UNITED STATES) 15:05 - 15:25 Heparanase and syndecan-1: promoters of aggressive Myeloma behaviour and targets for therapy R.D. SANDERSON (UNITED STATES) |
Tue, 3 May 15:45 - 16:15 | COFFEE BREAK BREAK | |
15:45 - 16:15 Visit of exhibition & poster area |
Tue, 3 May 16:15 - 18:15 | BONE DISEASE AND ANIMAL MODELS PLENARY SESSION I | Room GABRIEL DELORME |
Chair: R. BATAILLE (FRANCE), B. DURIE (UNITED STATES) 16:15 - 16:35 Introduction lecture: "Bone disease: From physiopathology to treatment" G.D. ROODMAN (UNITED STATES) 16:35 - 16:50 Bone anabolism and tumor growth in Myeloma S. YACCOBY (UNITED STATES) 16:50 - 17:05 Effect of new anti-myeloma drugs on bone microenvironment cells N. GIULIANI (ITALY) 17:05 - 17:20 Mathematical descriptions of bone remodelling dynamics B.P. AYATI (UNITED STATES) 17:20 - 17:35 Dissecting the Multiple Myeloma tumor microenvironment: a novel in vivo platform P. TASSONE (ITALY) 17:35 - 17:50 Epigenetic changes of myeloma cells within the bone marrow microenvironment K. VANDERKERKEN (BELGIUM) |
Tue, 3 May 18:15 - 18:25 | PATIENT ASSOCIATION TALKS SPEECH | Room GABRIEL DELORME |
18:15 - 18:20 International Myeloma Foundation (IMF)S. NOVIS (UNITED STATES) 18:20 - 18:25 Multiple Myeloma Research Foundation (MMRF)W. CAPONE (UNITED STATES) |
Tue, 3 May 18:25 - 19:00 | IMS TRAVEL GRANT AWARDS & WALDENSTROM'S AWARD SPEECH | Room GABRIEL DELORME |
18:25 - 19:00 IMS TRAVEL GRANT AWARDS & WALDENSTROM'S AWARD INTRODUCED BYJ.L. HAROUSSEAU (FRANCE), R.A. KYLE (UNITED STATES) |
Tue, 3 May 19:00 - 19:30 | IMS GENERAL ASSEMBLY ASSEMBLY | Room GABRIEL DELORME |
Tue, 3 May 19:30 - 23:00 | WELCOME RECEPTION AT THE MUSEE DU LOUVRE SPEECH | MUSEE DU LOUVRE |
Wednesday May 4, 2011
Wed, 4 May 07:45 - 10:00 | NEWLY DIAGNOSED MYELOMA<65 YEARS: FACTS & QUESTIONS PLENARY SESSION III | Room GABRIEL DELORME |
Chair: M. BOCCADORO (ITALY), V. HUNGRIA (BRAZIL) 07:45 - 08:15 How I treat a patient eligible for high dose therapy and auto-transplant?M. CAVO (ITALY) 08:15 - 10:00 What are the current asked questions? COOPERATIVE GROUPS 08:15 - 08:25 - EMNTG-Pethema/GEML. ROSIÑOL (SPAIN) 08:25 - 08:35 - CTN-BMTS. GIRALT (UNITED STATES) 08:35 - 08:45 - EMNTG-MRCG.J. MORGAN (UNITED KINGDOM) 08:45 - 08:55 - GMMGH. GOLDSCHMIDT (GERMANY) 08:55 - 09:05 - EMNTG-HOVON-GIMEMAM. CAVO (ITALY), P. SONNEVELD (NETHERLANDS) 09:05 - 09:15 - ArkansasB. BARLOGIE (UNITED STATES) 09:15 - 09:25 - IFM-DFCIP. MOREAU (FRANCE) |
Wed, 4 May 10:00 - 10:30 | COFFEE BREAK BREAK | |
10:00 - 10:30 Visit of exhibition & poster area |
Wed, 4 May 10:30 - 12:30 | CELGENE SYMPOSIUM - THE CONTINUUM OF CARE FOR THE MULTIPLE MYELOMA PATIENT SYMPOSIUM | Room GABRIEL DELORME |
Chair: K.C. ANDERSON (UNITED STATES), M. BOCCADORO (ITALY) 10:30 - 10:45 Welcome and introduction: The changing dynamic of Multiple Myeloma treatmentM. BOCCADORO (ITALY) 10:45 - 11:05 Mechanisms of action and disease: intercellular events and immunomodulationS. LENTZSCH (UNITED STATES) 11:05 - 11:25 Mechanisms of action and disease: immune synapseD.M. DAVIS (UNITED KINGDOM) 11:25 - 11:45 Optimizing current therapeutic options for relapsed/refractory Multiple MyelomaM.A. DIMOPOULOS (GREECE) 11:45 - 12:05 The evidence supporting continuous therapy in Multiple MyelomaS. GIRALT (UNITED STATES) 12:05 - 12:25 From bench to bedside: combination regimens in the present and future management of Multiple MyelomaK.C. ANDERSON (UNITED STATES) 12:25 - 12:30 CloseK.C. ANDERSON (UNITED STATES) |
Wed, 4 May 12:30 - 14:00 | LUNCH BREAK | |
12:30 - 14:00 Visit of exhibition & poster area |
Wed, 4 May 14:00 - 16:00 | HIGH-RISK ENTITIES OF MYELOMA: FROM BIOLOGY TO TREATMENT PLENARY SESSION I | Room GABRIEL DELORME |
Chair: M. KUEHL (UNITED STATES), A.K. STEWART (UNITED STATES) 14:00 - 14:20 t(4&14) and genomic instability in high-risk Myeloma P.L. BERGSAGEL (UNITED STATES) 14:20 - 14:40 The molecular biology of the MMSET protein of t(4-14) Myeloma J.D. LICHT (UNITED STATES) 14:40 - 15:00 Whole Genome Sequencing in high-risk Myeloma A.K. STEWART (UNITED STATES) 15:00 - 15:20 What is GEP-defined high-risk Myeloma? B. BARLOGIE (UNITED STATES) 15:20 - 15:30 The implications of High-risk Myeloma to therapy G.J. MORGAN (UNITED KINGDOM) 15:30 - 15:40 Allogeneic stem cell transplantation for high-risk Myeloma H. EINSELE (GERMANY) |
Wed, 4 May 16:00 - 17:00 | DEBATE: SHOULD WE TREAT SOME PATIENTS WITH STAGE I MM? DEBATE | Room GABRIEL DELORME |
Chair: M.A. GERTZ (UNITED STATES) 16:20 - 16:40 S. LONIAL (UNITED STATES) |
Wed, 4 May 17:00 - 17:30 | COFFEE BREAK BREAK | |
17:00 - 17:30 Visit of exhibition & poster area |
Wed, 4 May 17:30 - 19:00 | PRACTICAL ASPECTS ON THE MANAGEMENT OF MYELOMA BONE DISEASE PLENARY SESSION I | Room GABRIEL DELORME |
Chair: R. HÁJEK (CZECH REPUBLIC), M. BEKSAC (TURKEY) 17:30 - 17:50 Introduction lecture: "Bone imaging in Myeloma: old scaffolds and new avenues" M.A. DIMOPOULOS (GREECE) 17:50 - 18:00 Whole-body MRI in Myeloma J. HILLENGASS (GERMANY) 18:00 - 18:10 Bisphosphonates: Can the Dose be Lowered? P. GIMSING (DENMARK) 18:10 - 18:20 Zoledronic Acid in the Management of Myeloma J.A. CHILD (UNITED KINGDOM) 18:20 - 18:30 Osteonecrosis of the Jaw N. RAJE (UNITED STATES) 18:30 - 18:40 Should we use markers of bone remodelling in Myeloma? Which one and when? E. TERPOS (GREECE) |
Wed, 4 May 19:00 - 20:30 | MYELOMA CAST NEPHROPATHY & AL AMYLOIDOSIS PLENARY SESSION I | Room GABRIEL DELORME |
Chair: R. COMENZO (UNITED STATES), G. MERLINI (ITALY) 19:00 - 19:25 Introduction lecture: "Therapeutic elimination of amyloid deposits: is it possible?" M.B. PEPYS (UNITED KINGDOM) 19:25 - 19:45 Management of AL amyloidosis in 2011 G. MERLINI (ITALY) 19:45 - 20:15 Myeloma cast nephropathyN. LEUNG (UNITED STATES), F. BRIDOUX (FRANCE), C.A. HUTCHISON (UNITED KINGDOM) |
Wed, 4 May 20:30 - 22:00 | PRIME ONCOLOGY EDUCATIONAL POSTER SESSION RECEPTION Myeloma Therapy: Strategies in Evolution SYMPOSIUM | Room SOUFFLOT |
Co-chair: J.F. SAN MIGUEL (SPAIN), M. BOCCADORO (ITALY) 20:30 - 21:00 RECEPTION AND POSTER VIEWING COMPARE-Results of a Randomized Study to Assess the Renal Safety and Efficacy of Ibandronate and Zoledronate in Multiple Myeloma PatientsM. KROPFF (GERMANY) Optimizing Bone Disease in Myeloma: Zoledronic Acid Plus Thalidomide Combinations Improves Survival and Bone Endpoints: Results of the MRC Myeloma IX TrialG.J. MORGAN (UNITED KINGDOM) The Immunomodulatory Drugs Lenalidomide and Pomalidomide Inhibit Multiple Myeloma-Induced Osteoclast Formation and RANKL/OPG Ratio In Myeloma Microenvironment Targeting the Expression of Adhesion MoleculesM. BOLZONI (ITALY) Comparative Effectiveness of Bisphosphonates in Multiple MyelomaB. DJULBEGOVIC (UNITED STATES) PANORAMA 2: A Phase II Study of Panobinostat (LBH589) in Combination with Bortezomib (BTZ) and Dexamethasone (DEX) in Patients with Relapsed and BTZ-Refractory Multiple Myeloma (MM)M. ALSINA (UNITED STATES) Phase Ib Study of Oral Panobinostat (LBH589) plus Intravenous Bortezomib in Patients (Pts) with Relapsed (Rel) or Rel and Refractory (Ref) Multiple MyelomaJ.F. SAN MIGUEL (SPAIN) Elotuzumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed Multiple Myeloma: Interim Results of Phase 2 StudyP.G. RICHARDSON (UNITED STATES) Melphalan, Thalidomide and Prednisone (MPT) Combined with Oral Panobinostat in Patients with Relapsed/Refractory MM: A Phase I-II StudyM. OFFIDANI (ITALY) Phase I Study of Vorinostat, Lenalidomide, and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Excellent Tolerability and Promising Activity in a Heavily Pretreated PopulationP.G. RICHARDSON (UNITED STATES) Results of PX-171-003-A1, An Open-Label, Single-Arm, Phase 2 (Ph 2) Study of Carfilzomib (CFZ) in Patients (pts) with Relapsed and Refractory Multiple Myeloma (MM)S. LONIAL (UNITED STATES) 21:00 - 21:30 CLINICAL INSIGHTS IN BONE-TARGETED THERAPY FOR MULTIPLE MYELOMAG.J. MORGAN (UNITED KINGDOM) 21:30 - 22:00 EMERGING OPTIONS FOR RELAPSED/REFRACTORY MULTIPLE MYELOMAS. LONIAL (UNITED STATES)
|
Thursday May 5, 2011
Thu, 5 May 07:45 - 10:00 | NEWLY DIAGNOSED MYELOMA>65 YEARS: FACTS & QUESTIONS PLENARY SESSION III | Room GABRIEL DELORME |
Chair: A. PALUMBO (ITALY), D.E. REECE (CANADA) 07:45 - 08:15 How I treat a patient NOT eligible for high dose therapy and auto-transplantation? S.V. RAJKUMAR (UNITED STATES) 08:15 - 09:25 What are the current asked questions? COOPERATIVE GROUPS 08:15 - 08:25 - EMNTG-GIMEMAA. PALUMBO (ITALY) 08:25 - 08:35 - EMNTG-Pethema/GEMM.V. MATEOS (SPAIN) 08:35 - 08:45 - EMNTG-DSMMC. STRAKA (GERMANY) 08:45 - 08:55 - US intergroupD. WEBER (UNITED STATES) 08:55 - 09:05 - EMNTG-Hovon/NordicS. ZWEEGMAN (NETHERLANDS) 09:05 - 09:15 - EMNTG-MRCF. DAVIES (UNITED KINGDOM) |
Thu, 5 May 10:00 - 10:30 | COFFEE BREAK BREAK | |
10:00 - 10:30 Visit of exhibition & poster area |
Thu, 5 May 10:30 - 12:30 | MILLENNIUM TAKEDA & JANSSEN SATELLITE SYMPOSIUM : "Optimizing Patient Outcomes Through Individualized Treatment Approaches : Phase III Data" SYMPOSIUM | Room GABRIEL DELORME |
Co-chair: R. ORLOWSKI (UNITED STATES), P. SONNEVELD (NETHERLANDS)
Additionnal Faculty: P.G. RICHARDSON (UNITED STATES), M. MOHTY (FRANCE), K. COLSON (UNITED STATES), M. DELFORGE (BELGIUM) 10:30 - 10:35 INTRODUCTIONP. SONNEVELD (NETHERLANDS) 10:35 - 11:35 CLINICAL IMPLICATIONS OF PROTEASOME INHIBITION IN MULTIPLE MYELOMA: A DECADE OF CLINICAL EXPERIENCE 10:35 - 10:45 Treatment goals and clinical outcomes in Multiple MyelomaR. ORLOWSKI (UNITED STATES) 10:45 - 11:05 Improving outcomes for patients not eligible for transplantationP.G. RICHARDSON (UNITED STATES) 11:05 - 11:25 The impact of proteasome inhibition in the transplant setting P. SONNEVELD (NETHERLANDS) 11:25 - 11:35 Panel discussionR. ORLOWSKI (UNITED STATES), P. SONNEVELD (NETHERLANDS) 11:35 - 12:25 ENHANCING PATIENT OUTCOME THROUGH OPTIMAL MANAGEMENT STRATEGIES: BASED ON PHASE III DATA 11:35 - 11:50 Overcoming adverse effects through individualized patient care M. MOHTY (FRANCE) 11:50 - 12:00 Practical considerations for patient managementK. COLSON (UNITED STATES) 12:00 - 12:15 Flexible dosing strategies and subcutaneous route of administration: Phase 3 dataM. DELFORGE (BELGIUM) 12:15 - 12:25 Panel discussionR. ORLOWSKI (UNITED STATES), P. SONNEVELD (NETHERLANDS) 12:25 - 12:30 SUMMARY AND CLOSING REMARKS: FUTURE PERSPECTIVES IN MULTIPLE MYELOMA THERAPY R. ORLOWSKI (UNITED STATES)
|
Thu, 5 May 12:30 - 13:30 | LUNCH BREAK | |
12:30 - 13:30 Visit of Exhibition & poster area |
Thu, 5 May 13:30 - 15:30 | NEW DRUGS AND THERAPEUTIC APPROACHES PLENARY SESSION I | Room GABRIEL DELORME |
Chair: J.L. HAROUSSEAU (FRANCE), J.F. SAN MIGUEL (SPAIN) 13:30 - 13:55 Introduction lectureK.C. ANDERSON (UNITED STATES) 13:55 - 14:07 Pre-clinical evaluation and identification of novel therapeutics A. SPENCER (AUSTRALIA) 14:07 - 14:19 Preclinical basis for 2nd generation proteasome inhibitorsK.C. ANDERSON (UNITED STATES) 14:19 - 14:31 Carfilzomib and other new proteasome inhibitors: Clinical data A.J. JAKUBOWIAK (UNITED STATES) 14:31 - 14:43 Current status of pomalidomide in Myeloma M.Q. LACY (UNITED STATES) 14:43 - 14:55 Histone deacetylase inhibitors E.M. OCIO (SPAIN) 14:55 - 15:07 Monoclonal antibodies in the treatment of Myeloma S. JAGANNATH (UNITED STATES) |
Thu, 5 May 15:30 - 17:00 | SECONDARY MALIGNANCIES IN MYELOMA: AN EMERGING ISSUE? HIGHLIGHT | Room GABRIEL DELORME |
Chair: J.P. FERMAND (FRANCE) 15:30 - 15:40 IntroductionJ.P. FERMAND (FRANCE) 15:40 - 15:55 Maintenance treatment with lenalidomide after transplantation for myeloma: analysis of secondary malignancies within the IFM 2005-02 trial M. ATTAL (FRANCE) 15:55 - 16:10 Phase III intergroup study of lenalidomide versus placebo maintenance therapy following single autologous stem cell transplant (ASCT) for Multiple Myeloma (MM): CALGB ECOG BMT-CTN 100104 P.L. MCCARTHY JR (UNITED STATES) 16:10 - 16:25 Secondary malignancies in elderly myeloma patients A. PALUMBO (ITALY) 16:25 - 16:30 Retrospective analysis of the long term safety of lenalidomide (LEN) ± dexamethasone (DEX) in relapsed/refractory Myeloma (RRMM) patients (PTS): analysis of pooled data and incidence rates (IR) of second primary malignancy (SPM) G.J. MORGAN (UNITED KINGDOM) 16:30 - 16:35 Risk of subsequent primary malignancies in patients with multiple myeloma before and after the introduction of novel therapies: a population-based study in Sweden O. LANDGREN (UNITED STATES)
|
Thu, 5 May 17:00 - 17:30 | COFFEE BREAK BREAK | |
17:00 - 17:30 Visit of exhibition & poster area |
Thu, 5 May 17:30 - 18:40 | PLENARY ABSTRACT SESSION I PLENARY ABSTRACT SESSION | Room GABRIEL DELORME |
Chair: J. BLADÉ (SPAIN), G. GAHRTON (SWEDEN) |
Thu, 5 May 19:00 - 20:30 | MONOCLONAL IMMUNOGLOBULIN AND THE NERVE, WALDENSTROM'S MACROGLOBULINEMIA PLENARY SESSION I | Room GABRIEL DELORME |
Chair: B. SIROHI (INDIA), S. TREON (UNITED STATES) 19:00 - 19:20 Neuropathy in monoclonal gammopathy E. NOBILE-ORAZIO (ITALY) 19:20 - 19:40 Poems syndrome A. DISPENZIERI (UNITED STATES) 19:40 - 20:10 Update in the treatment of WMS. TREON (UNITED STATES), V. LEBLOND (FRANCE) |
Friday May 6, 2011
Fri, 6 May 07:45 - 10:00 | CONSENSUS REPORT PLENARY SESSION III | Room GABRIEL DELORME |
Chair: N. MUNSHI (UNITED STATES) 07:45 - 10:00 Diagnosis criteria & criteria for treatment and retreatment Supportive care including: - Vaccination and infection prophylaxis E. ANAISSIE (UNITED STATES) - Management of anemia H. LUDWIG (AUSTRIA) - Vein thrombosis A. PALUMBO (ITALY) - Bone disease G.D. ROODMAN (UNITED STATES) |
Fri, 6 May 10:00 - 10:30 | COFFEE BREAK BREAK | |
10:00 - 10:30 Visit of exhibition & poster area |
Fri, 6 May 10:30 - 12:45 | PLENARY ABSTRACT SESSION II PLENARY ABSTRACT SESSION | Room GABRIEL DELORME |
Chair: M. ATTAL (FRANCE), P.G. RICHARDSON (UNITED STATES) 10:30 - 11:00 INTRODUCTION LECTURE: Initial genome sequencing: a new step in understanding Myeloma?A. FUTREAL (UNITED KINGDOM)
|
Fri, 6 May 12:45 - 15:00 | CLOSING CEREMONY & COCKTAIL SPEECH | Room GABRIEL DELORME |
12:45 - 13:30 Under the Presidency ofR.A. KYLE (UNITED STATES), K.C. ANDERSON (UNITED STATES) Closing Talk by the Organizing CommitteeJ.P. FERMAND (FRANCE), T. FACON (FRANCE), P. MOREAU (FRANCE) PATIENT ASSOCIATION TALKS Association Française des Malades du Myelome Multiple (AF3M)B. FAVRE (FRANCE), D. JORDAN (FRANCE) International Myeloma Foundation (IMF)S. NOVIS (UNITED STATES) Multiple Myeloma Research Foundation (MMRF)S. TYGHTER (UNITED STATES) Introducing IMW 2013K. SHIMIZU (JAPAN) |
|
© 2008 -